JPRN-UMIN000029981已完成4 期
The study to evaluate ShorT and OPtimal duration of Dual AntiPlatelet Therapy for the patients with ACS - The study to evaluate ShorT and OPtimal duration of Dual AntiPlatelet Therapy for the patients with ACS (STOPDAPT-2 ACS)
Kyoto University, Graduate School of Medicine, Department of Cardiovascular Medicine0 个研究点目标入组 3,008 人开始时间: 2018年3月1日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 3,008
研究概览
简要总结
In the pooled 4136 patients, 2058 were assigned into the 1-month DAPT group and 2078 were assigned into the 12-month DAPT group. The 1-year incidence rate of the primary end point comprising cardiovascular and bleeding events was 3.2% in those in the 1-month DAPT group and 2.8% in the 12-month DAPT group, which did not meet the noninferiority of the 1-month DAPT group.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients requiring oral anticoagulants 2. Patients with medical history of intracranial hemorrhage 3. Patients who have experienced serious complications (MI, stroke, and major bleeding) during hospital stay post-PCI 4. Patients with DES other than Xience implanted in PCI performed at the time of enrollment 5. Patients confirmed to have no tolerability to clopidogrel before enrollment 6. Patients requiring continuous administration of antiplatelet drugs (PDE3 inhibitors, prostaglandin preparations, etc.) other than aspirin and P2Y12 receptor inhibitors (prasugrel, clopidogrel, and ticlopidine) at the time of enrollment 7. Patients with coronary bioabsorbable vascular scaffold (BVS) implanted prior to or at the time of enrollment
研究者
相似试验
已完成
4 期
ShorT and OPtimal duration of Dual AntiPlatelet Therapy-2 studyJPRN-UMIN000019948Kyoto University, Graduate School of Medicine, Department of Cardiovascular Medicine3,045
招募中
不适用
Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery DiseaseNCT06075420Genoss Co., Ltd.1,000
终止
3 期
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer PatientsProstate CancerNCT00133224Cell Genesys408
已完成
4 期
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 StudyCoronary Artery DiseaseNCT02619760Kyoto University, Graduate School of Medicine3,045
已完成
不适用
The DTG-SWITCH Study: Longitudinal Analysis of Virologic Failure and Drug Resistance at and After Switching to Dolutegravir-based First-line ARTHivDrug ResistancyVirologic FailureNCT04612452University of Bern2,820